{
    "clinical_study": {
        "@rank": "70635", 
        "arm_group": {
            "arm_group_label": "Ramucirumab + FOLFOX4", 
            "arm_group_type": "Experimental", 
            "description": "Ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles.  Participants may continue to receive treatment until discontinuation criteria are met."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to determine if the advised dose of ramucirumab is safe to\n      be taken with chemotherapy treatment in participants with advanced liver tumors."
        }, 
        "brief_title": "A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological diagnosis of hepatocellular carcinoma (HCC) or imaging\n             findings consistent with HCC in a participant with liver cirrhosis and\n             alpha-fetoprotein > 200 nanogram per milliliter\n\n          -  At least 1 measurable or non-measurable lesion\n\n          -  Child-Pugh A\n\n          -  Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to\n             locoregional therapy or refractory to locoregional therapy\n\n          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1\n\n          -  Have not received previous systemic therapy for advanced HCC\n\n          -  Have resolution to Grade \u22641 of all clinically significant toxic effects of prior\n             locoregional therapy\n\n          -  Adequate organ function including: Absolute neutrophil coun t\u22651.5\u00d7109/liter (L),\n             hemoglobin \u22659 gram/deciliter, and platelets \u226590\u00d7109/L; Total bilirubin level \u22641.5 the\n             upper limit of the normal range (ULN), aspartate transaminase and alanine\n             transaminase \u22645 ULN, albumin >28 gram/L; Serum creatinine level \u22641.5 ULN; or\n             calculated serum creatinine clearance \u226550 milliliter/minute; International Normalized\n             Ratio\u22641.5 and partial thromboplastin time \u22645 seconds above ULN\n\n          -  The urinary protein is \u2264 1+. If \u2265 2+ proteinuria, the 24-hour urine protein is <1000\n             milligram\n\n          -  An estimated life expectancy of at least 12 weeks\n\n        Exclusion Criteria:\n\n          -  Received any investigational therapy or non-approved drug within 28 days prior to\n             enrollment\n\n          -  Undergone major surgery within 28 days prior to enrollment, or undergone central\n             venous access device placement within 7 days prior to enrollment\n\n          -  Undergone hepatic locoregional therapy within 28 days prior to enrollment\n\n          -  Undergone radiation to any nonhepatic site within 14 days prior to enrollment\n\n          -  Prior liver transplant\n\n          -  Fibrolamellar carcinoma or cholangiocellular carcinoma\n\n          -  Received any transfusion, blood component preparation, erythropoietin, albumin\n             preparation, or granulocyte-colony stimulating factors within 14 days prior to\n             enrollment\n\n          -  Receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or\n             similar agents\n\n          -  Receiving ongoing therapy with nonsteroidal anti-inflammatory agents or other\n             antiplatelet agents.\n\n          -  Known human immunodeficiency virus infection or acquired immunodeficiency\n             syndrome-related illness\n\n          -  Active or uncontrolled clinically serious infection\n\n          -  Uncontrolled thrombotic or hemorrhagic disorder\n\n          -  Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to\n             enrollment\n\n          -  History of gastrointestinal perforation or obstruction\n\n          -  History of or current hepatic encephalopathy or current clinically meaningful ascites\n\n          -  Known allergy to monoclonal antibody, fluorouracil, oxaliplatin or their excipients\n\n          -  Interstitial pneumonia or interstitial fibrosis of the lung\n\n          -  Central nervous system metastases or carcinomatous meningitis\n\n          -  Known history of dihydropyrimidine dehydrogenase deficiency\n\n          -  Symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or\n             poorly controlled cardiac arrhythmia\n\n          -  Experienced any arterial thromboembolic event\n\n          -  Uncontrolled arterial hypertension\n\n          -  Grade 3-4 venous thromboembolic events occurring within 3 months prior to enrollment\n\n          -  Experienced any grade 3-4 gastrointestinal bleeding or any variceal bleeding episode\n             in the 3 months prior to enrollment requiring transfusion, endoscopic or operative\n             intervention\n\n          -  Esophageal or gastric varices that require immediate intervention or represent a high\n             bleeding risk\n\n          -  Pre-existing grade \u2265 2 motor or sensory neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069041", 
            "org_study_id": "15233", 
            "secondary_id": "I4T-CR-JVCQ"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ramucirumab + FOLFOX4", 
                "description": "Administered IV.", 
                "intervention_name": "Ramucirumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "IMC-1121B", 
                    "LY3009806"
                ]
            }, 
            {
                "arm_group_label": "Ramucirumab + FOLFOX4", 
                "description": "Administered IV.", 
                "intervention_name": "FOLFOX4", 
                "intervention_type": "Drug", 
                "other_name": "FOLFOX4 (leucovorin + fluorouracil + oxaliplatin)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Kuei Shan Hsiang", 
                        "country": "Taiwan", 
                        "zip": "33305"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan", 
                        "zip": "70403"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through study completion (estimated as 8 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069041"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Cycle 9, Day 1 (Cycle = 2 weeks)"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of Ramucirumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Cycle 9, Day 1 (Cycle = 2 weeks)"
            }, 
            {
                "measure": "Number of Participants with Anti-Ramucirumab Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Cycle 9, Day 1 (Cycle = 2 weeks)"
            }, 
            {
                "measure": "Objective Responses Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Response to disease progression or death (estimated as 2 months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}